Research analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research note issued to investors on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday, November 15th.
View Our Latest Report on Aethlon Medical
Aethlon Medical Stock Down 7.0 %
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Further Reading
- Five stocks we like better than Aethlon Medical
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.